G007-LK: Precision Tankyrase 1/2 Inhibition for Wnt/β-catenin and APC Mutation Cancer Research

Executive Summary: G007-LK is a small-molecule inhibitor that targets tankyrase 1/2 with high nanomolar potency, selectively suppressing poly(ADP-ribosyl)ation and Wnt/β-catenin signaling in cancer models (APExBIO). It induces β-catenin degradation and stabilizes AXIN1/2, leading to pronounced suppression of colorectal tumor growth in APC mutation models (Jia et al., 2017). G007-LK effectively inhibits Wnt signaling in Wnt3a-induced HEK 293 cells and SW480 colorectal cancer cells, with IC₅₀ values in the nanomolar to submicromolar range. In vivo, G007-LK reduces tumor growth and β-catenin levels in COLO-320DM xenograft mice. These properties make G007-LK a gold-standard tankyrase inhibitor for dissecting the Wnt/β-catenin axis and investigating tankyrase-dependent cell cycle control across cancer biology.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribosyl) polymerases that regulate Wnt/β-catenin signaling, cell cycle progression, and telomere homeostasis. In cancer, especially APC mutation-driven colorectal tumors and hepatocellular carcinoma (HCC), tankyrase expression and activity are frequently elevated (Jia et al., 2017). Tankyrases control β-catenin turnover by mediating AXIN degradation, leading to β-catenin accumulation and oncogenic transcription. Inhibiting tankyrases stabilizes AXIN1/2, promoting β-catenin degradation and suppressing Wnt-driven proliferation. G007-LK, developed and marketed by APExBIO, is a selective small-molecule inhibitor that enables targeted dissection of these pathways in research settings (Product Page).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds to the NAD⁺-binding pocket of TNKS1 and TNKS2, inhibiting their auto-poly(ADP-ribosyl)ation activity with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) (APExBIO). This inhibition prevents PARylation-dependent degradation of AXIN1/2, stabilizing these scaffolding proteins and facilitating the assembly of β-catenin destruction complexes. In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt reporter (ST-Luc) activity with an IC₅₀ of 0.05 μM, confirming potent cellular inhibition. In APC-mutant colorectal cancer cell lines (e.g., SW480), G007-LK induces degradasome formation involving phosphorylated β-catenin, β-TrCP, and ubiquitin, thereby enhancing β-catenin degradation and lowering its cytosolic and nuclear levels. In vivo, G007-LK reduces TNKS1/2 and β-catenin expression and stabilizes AXIN1/2 in tumor tissues, directly translating molecular inhibition to tumor growth suppression.

Evidence & Benchmarks

• G007-LK inhibits tankyrase auto-PARylation in vitro with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) (APExBIO).
• Suppresses Wnt/β-catenin signaling in Wnt3a-induced HEK 293 cells (IC₅₀ = 0.05 μM) (APExBIO).
• Induces β-catenin degradation and AXIN stabilization in APC-mutant SW480 colorectal cancer cells (Jia et al., 2017).
• Reduces tumor growth, TNKS1/2, and β-catenin protein levels in COLO-320DM xenograft mouse models at 20–40 mg/kg (APExBIO).
• Downregulates YAP and Wnt/TEAD target genes and upregulates AMOTL1/2, supporting Hippo pathway modulation (Jia et al., 2017).
• Synergizes with MEK and AKT inhibitors to further suppress cancer cell proliferation in HCC models (Jia et al., 2017).
• Demonstrates high solubility in DMSO (≥26.5 mg/mL) but is insoluble in water and ethanol (APExBIO).

For additional mechanistic analysis and translational insights, compare with G007-LK Tankyrase 1/2 Inhibitor: Transforming Translation, which emphasizes cross-pathway regulation and workflow optimization; this article provides a more consolidated benchmark across diverse cancer models. For practical assay guidance, see Enhancing Cell Assay Precision with G007-LK Tankyrase 1/2, while the current article extends its focus to in vivo and pathway-specific endpoints.

Applications, Limits & Misconceptions

G007-LK is used for:

• Dissecting Wnt/β-catenin signaling in cellular and animal models.
• Studying APC mutation-driven colorectal cancer and hepatocellular carcinoma.
• Investigating Hippo/YAP pathway modulation and AMOTL1/2 stabilization.
• Evaluating β-catenin degradation and AXIN stabilization for cancer therapy research.
• Inhibiting cell cycle progression and colony formation in cancer cell assays.

Common Pitfalls or Misconceptions

• Not effective in non-tankyrase-driven cancers: G007-LK efficacy depends on tankyrase-mediated β-catenin regulation; tumors lacking this axis may show minimal response.
• Solubility limitations: G007-LK is insoluble in water and ethanol, requiring DMSO for stock solutions; improper solvent use may lead to precipitation or reduced bioactivity (APExBIO).
• Short-term solution stability: Working solutions should be prepared fresh; long-term storage in solution is discouraged due to potential degradation.
• Does not inhibit all PARP enzymes: G007-LK is selective for TNKS1/2 and does not broadly inhibit other PARP family members.
• Off-target effects at high concentrations: Exceeding recommended concentrations can induce cytotoxicity unrelated to tankyrase inhibition.

Workflow Integration & Parameters

Preparation: Dissolve G007-LK powder at ≥26.5 mg/mL in DMSO to create stock solutions; store at -20°C. Avoid aqueous or ethanol solvents to prevent precipitation. Use stock solutions within a short timeframe for optimal results.

Cellular assays: Apply G007-LK at 0.05–1 μM for Wnt inhibition in HEK 293 or SW480 cells. For colony formation or proliferation assays, titrate concentration based on cell type and endpoint sensitivity. For in vivo studies, administer 20–40 mg/kg in xenograft models, monitoring tumor growth and pathway target protein levels.

G007-LK is compatible with combination studies (e.g., MEK/AKT inhibitors) to evaluate pathway crosstalk. For detailed protocol comparisons, see G007-LK: Advanced Tankyrase 1/2 Inhibitor for Mechanistic..., which provides additional mechanistic and translational context not covered here.

Conclusion & Outlook

G007-LK, supplied by APExBIO, is a validated, selective tankyrase 1/2 inhibitor that enables high-fidelity, quantitative modulation of the Wnt/β-catenin and Hippo/YAP pathways in cancer research. Its robust efficacy in APC mutation colorectal cancer and HCC models, along with well-characterized parameters for in vitro and in vivo use, make it an essential reagent for mechanism-driven studies and preclinical drug discovery. While not universally effective in all cancer types, its specificity, well-documented mechanism, and compatibility with combinatorial approaches cement its role as a reference standard in pathway biology research. Ongoing studies will further elucidate its utility in complex tumor microenvironments and therapy-resistant cancers.